Skip to content

    Recently Viewed



      What are autoantibodies?

      More than 200 million people worldwide are living with an autoantibody disease, which occurs when the body attacks its own cells, tissues and proteins.

      Share Article
      share to

      Antibodies are proteins that guard against substances—such as bacteria, fungi, viruses and toxins—that enter your body like foreign invaders. Antibodies protect you by attaching to those invaders (also known as antigens) and triggering your body’s natural immune response to destroy them.

      You can think of autoantibodies as misguided, or pathogenic, antibodies. Instead of reacting to the antigen, they respond to your body’s own proteins, leading—in some cases—to an abnormal immune response that attacks the cells, tissues and organs of your body and contributes to the development of autoantibody diseases.
      “Autoantibody diseases comprise a large and varied group of more than 80 chronic conditions,” says Katie Abouzahr, Vice President, Autoantibody Portfolio Development Leader, Janssen Research and Development. They include hemolytic disease of the fetus and newborn, in which a mother’s immune system attacks her unborn child’s blood cells; warm autoimmune hemolytic anemia, which involves the premature destruction of healthy red blood cells; and myasthenia gravis, a disorder that’s characterized by fluctuating weakness in the skeletal muscles.

      Autoantibodies can be markers of autoimmune diseases like rheumatoid arthritis or lupus. In fact, more than 2.5% of the population is affected by an autoantibody-driven autoimmune disease.

      “Autoantibody diseases represent a significant area of unmet patient need,” says Abouzahr. “There are 240 million people worldwide, approximately 3% of the population, who suffer from autoantibody diseases, many without safe and effective treatment options.”

      That’s why Johnson & Johnson is working on immunological advances to help address the need.

      Watch this video to learn more about autoantibodies and their role in rare diseases:

      Are You Affected by an Autoantibody Disease?

      Learn more about two clinical research studies and eligibility requirements.

      More from Johnson & Johnson

      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      Caring & giving
      Sam Seavey piloting an aircraft from the cockpit

      3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection

      In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
      Health & wellness
      3D human heart anatomy illustrations

      Do you know what heart failure is? (Hint: It’s probably not what you think)

      For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.